Cargando…

The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma

Microtubule-targeting agents (MTAs) are effective drugs for cancer treatment. A novel diaryl [1,2]oxazole class of compounds binding the colchicine site was synthesized as cis-restricted-combretastatin-A-4-analogue and then chemically modified to have improved solubility and a wider therapeutic inde...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grillone, Katia, Riillo, Caterina, Rocca, Roberta, Ascrizzi, Serena, Spanò, Virginia, Scionti, Francesca, Polerà, Nicoletta, Maruca, Annalisa, Barreca, Marilia, Juli, Giada, Arbitrio, Mariamena, Di Martino, Maria Teresa, Caracciolo, Daniele, Tagliaferri, Pierosandro, Alcaro, Stefano, Montalbano, Alessandra, Barraja, Paola, Tassone, Pierfrancesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499408/ https://www.ncbi.nlm.nih.gov/pubmed/36142133 http://dx.doi.org/10.3390/ijms231810222

Ejemplares similares

miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy
por: Di Martino, Maria Teresa, et al.
Publicado: (2021)

miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma
por: Caracciolo, Daniele, et al.
Publicado: (2021)

TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma
por: Scionti, Francesca, et al.
Publicado: (2023)

Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin
por: Caracciolo, Daniele, et al.
Publicado: (2022)

Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes
por: Scionti, Francesca, et al.
Publicado: (2022)

The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas
por: Polerà, Nicoletta, et al.
Publicado: (2023)

Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats
por: Di Martino, Maria Teresa, et al.
Publicado: (2020)

Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma
por: Caracciolo, Daniele, et al.
Publicado: (2020)

Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice
por: Arbitrio, Mariamena, et al.
Publicado: (2020)

A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells
por: Riillo, Caterina, et al.
Publicado: (2022)

MMRF-CoMMpass Data Integration and Analysis for Identifying Prognostic Markers
por: Settino, Marzia, et al.
Publicado: (2020)

Non-coding RNAs in cancer: platforms and strategies for investigating the genomic “dark matter”
por: Grillone, Katia, et al.
Publicado: (2020)

A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer
por: Riillo, Caterina, et al.
Publicado: (2023)

Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221
por: Di Martino, Maria Teresa, et al.
Publicado: (2019)

The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives
por: Caracciolo, Daniele, et al.
Publicado: (2023)

Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma
por: Stamato, Maria Angelica, et al.
Publicado: (2017)

DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine
por: Arbitrio, Mariamena, et al.
Publicado: (2016)

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma
por: Cucè, Maria, et al.
Publicado: (2019)

Mouse models of multiple myeloma: technologic platforms and perspectives
por: Rossi, Marco, et al.
Publicado: (2018)

Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties
por: Rocca, Roberta, et al.
Publicado: (2022)

Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer’s Achilles’ Heel
por: Caracciolo, Daniele, et al.
Publicado: (2021)

Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity
por: Staropoli, Nicoletta, et al.
Publicado: (2023)

DMET(TM) Genotyping: Tools for Biomarkers Discovery in the Era of Precision Medicine
por: Agapito, Giuseppe, et al.
Publicado: (2020)

BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?
por: Tagliaferri, Pierosandro, et al.
Publicado: (2009)

Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives
por: Arbitrio, Mariamena, et al.
Publicado: (2018)

MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches
por: Amodio, Nicola, et al.
Publicado: (2018)

DMET-Analyzer: automatic analysis of Affymetrix DMET Data
por: Guzzi, Pietro Hiram, et al.
Publicado: (2012)

A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics
por: Staropoli, Nicoletta, et al.
Publicado: (2022)

Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?
por: Cucinotto, Iole, et al.
Publicado: (2013)

OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes
por: Agapito, Giuseppe, et al.
Publicado: (2016)

Lynch Syndrome Biopathology and Treatment: The Potential Role of microRNAs in Clinical Practice
por: Ascrizzi, Serena, et al.
Publicado: (2023)

miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review
por: Di Martino, Maria Teresa, et al.
Publicado: (2022)

HSV-1 Glycoprotein D and Its Surface Receptors: Evaluation of Protein–Protein Interaction and Targeting by Triazole-Based Compounds through In Silico Approaches
por: Bivacqua, Roberta, et al.
Publicado: (2023)

Pyrrolo[2′,3′:3,4]cyclohepta[1,2-d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types
por: Spanò, Virginia, et al.
Publicado: (2020)

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia
por: Caracciolo, Daniele, et al.
Publicado: (2021)

Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts
por: Pitari, Maria Rita, et al.
Publicado: (2015)

miR-22 suppresses DNA ligase III addiction in multiple myeloma
por: Caracciolo, Daniele, et al.
Publicado: (2018)

Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study
por: Tassone, Pierfrancesco, et al.
Publicado: (2023)

From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology
por: Gallo Cantafio, Maria Eugenia, et al.
Publicado: (2018)

Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates
por: Gallo Cantafio, Maria Eugenia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vu491s8hnmnhir3etggd0geemj